Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
The observations are procedural in nature
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
Mindset disagrees with and denies the allegations set forth from Reunion.
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Subscribe To Our Newsletter & Stay Updated
